Loading page
Loading page
Loading substance route
More potent than LSD; reports indicate pronounced physical effects at higher doses including nausea and temperature dysregulation
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
ETH-LAD is not habit-forming and the desire to use it can actually decrease with use. Like most psychedelics, it is generally considered to have a built-in, self-regulating aspect, though isolated cases of abuse have been reported.
No physical dependence or withdrawal syndrome has been documented. As with other lysergamides, physical dependence is not expected to develop.
The exact toxic dose is unknown due to ETH-LAD being a research chemical with very little history of human usage. No toxic dosage has been established, though the substance is reported to be harsher to handle in overdose compared to LSD or other lysergamides.
Psychotic reactions including delusions and severe confusion have been reported primarily in overdose scenarios or when combined with other substances such as cannabis, stimulants, or lithium. At low to moderate doses with appropriate set and setting, psychotic episodes appear to be uncommon.
Seizure risk is largely extrapolated from reports associated with LSD use and is thought to mainly affect those who are genetically predisposed, particularly when accompanied by dehydration, fatigue, or undernourishment. Seizures are described as rare but may occur more readily in overdose situations.
ETH-LAD was first described in the scientific literature by Japanese researcher Tetsukichi Niwaguchi and colleagues in 1976. Nearly a decade later, American researchers Andrew J. Hoffman and David E. Nichols conducted preclinical pharmacological studies of the compound in 1985, examining its…
Not explicitly scheduled by name. However, it may fall under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act) as a structural analogue of LSD.
While not officially scheduled by name, it is controlled as a structural analogue of LSD under an amendment to drug legislation enacted on June 1, 2015.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation since December 1, 2015.
Specifically named in the Misuse of Drugs Act 1971 as a Class A controlled substance since January 7, 2015. Class A carries the most severe penalties, including up to 7 years imprisonment for possession.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production and import with intent to market, administration to others, and trading are criminally punishable. Possession is prohibited but not subject to criminal penalty.
Classified as a New Psychoactive Substance under Polish drug law. Both possession and distribution are prohibited.
Classified as a controlled drug under Turkish legislation. Possession, production, supply, and importation are all prohibited.
Not specifically scheduled under the Controlled Substances Act. However, as a structural analogue of LSD (Schedule I), sale for human consumption or use for illicit non-medical purposes may be prosecuted under the Federal Analogue Act.
9 sources cited
